Nexus Pharmaceu Patent-Cliff Exposure & CMS Drug Spending Portfolio

Nexus Pharmaceu (US): 2 reconciled FDA prescription therapies, $48K 2024 CMS Part D & Medicaid spend, and $1,650 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$48K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$48K
California HCAI SB 17 FilingsSpecialty launch notice ($1,650 intro WAC)